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Abstract
Background: Transcriptome sequencing using next-generation sequencing platforms will soon
be competing with DNA microarray technologies for global gene expression analysis. As a
preliminary evaluation of these promising technologies, we performed deep sequencing of cDNA
synthesized from the Microarray Quality Control (MAQC) reference RNA samples using Roche's
454 Genome Sequencer FLX.
Results: We generated more that 3.6 million sequence reads of average length 250 bp for the
MAQC A and B samples and introduced a data analysis pipeline for translating cDNA read counts
into gene expression levels. Using BLAST, 90% of the reads mapped to the human genome and 64%
of the reads mapped to the RefSeq database of well annotated genes with e-values ≤ 10
-20.W e
measured gene expression levels in the A and B samples by counting the numbers of reads that
mapped to individual RefSeq genes in multiple sequencing runs to evaluate the MAQC quality
metrics for reproducibility, sensitivity, specificity, and accuracy and compared the results with
DNA microarrays and Quantitative RT-PCR (QRTPCR) from the MAQC studies. In addition, 88%
of the reads were successfully aligned directly to the human genome using the AceView alignment
programs with an average 90% sequence similarity to identify 137,899 unique exon junctions,
including 22,193 new exon junctions not yet contained in the RefSeq database.
Conclusion: Using the MAQC metrics for evaluating the performance of gene expression
platforms, the ExpressSeq results for gene expression levels showed excellent reproducibility,
sensitivity, and specificity that improved systematically with increasing shotgun sequencing depth,
and quantitative accuracy that was comparable to DNA microarrays and QRTPCR. In addition, a
careful mapping of the reads to the genome using the AceView alignment programs shed new light
on the complexity of the human transcriptome including the discovery of thousands of new splice
variants.
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The goal of the Microarray Quality Control (MAQC)
project was to identify quality metrics for evaluating
gene expression measurement technologies [1]. The
MAQC study provided a set of reference RNA samples
with large numbers of differentially expressed genes
consisting of the commercially available A sample from
pooled human cell lines and the B sample from a pooled
human brain preparation. These two samples were
exhaustively analyzed on a number of different whole
genome microarray platforms and Quantitative Real-
Time PCR (QRTPCR) [1,2].
With the advent of the new "next-generation" sequen-
cing technologies, it is now practical to analyze gene
expression by the direct shotgun sequencing of com-
plementary DNA (cDNA) synthesized from RNA samples
[3,4]. This approach has already been applied to discover
novel gene sequences in the transcriptomes of human
cell lines [5] and plants [6,7] and to identify cancer
related Single Nucleotide Polymorphisms (SNPs) in
transcribed sequences in human cancer transcriptomes
[8]. More recently papers have appeared using this
technique to confirm predicted genes in the bacteria
[9] and to identify novel transcription products and to
quantify expression levels in the yeast [10,11], mouse
[12-14], human Hela cells [15], and the cerebellar cortex
of schizophrenic patients [16].
To provide a preliminary evaluation of the performance
of these promising technologies for gene expression
analysis, we performed deep sequencing of the Micro-
array Quality Control (MAQC) reference RNA samples
using Roche's 454 Genome Sequencer FLX (GS FLX)
[17]. For this study, we generated more than 3.6 million
sequence reads of average length 250 bp for cDNA
generated from the MAQC A and B samples [1]. Using
our ExpressSeq pipeline over 90% of the reads mapped
to the human genome and 64% of the reads mapped to
the RefSeq database of well annotated genes using BLAST
with e-values ≤ 10
-20, corresponding to at least 50 perfect
match bases. (Because of the long read lengths, more
stringent e-values, eg. 10
-50 or 10
-100,c o u l da l s ob eu s e d
for the BLAST searches, however these would begin to
miss reads that partially hit exons that are not already
contained in RefSeq.) By counting the numbers of reads
that map to individual genes we can measure the gene
expression levels in the two samples to evaluate the
MAQC quality metrics and compare the results with
DNA microarrays and QRTPCR.
We have also performed a careful mapping of the
transcriptome reads to the genome using the AceView
alignment programs used to construct the AceView
database of genes and alternative splice variants from
cDNA sequences in all public databases [18]. Many of
t h eG SF L Xr e a d ss p a n n e do n eo rm o r ee x o nj u n c t i o n s
recovering approximately 60% of the exon junctions
already annotated in the RefSeq database and 36% of the
exon junctions in the comprehensive AceView database.
In addition thousands of new exon junctions were
identified spanning standard introns in the genome that
have not been previously annotated in any public
databases. These additional results speak to the great
promise of deep transcriptome sequencing to rapidly
shed new light on the complexity of the eukaryotic
transcriptome.
Results
Mapping of reads to the RefSeq, CCDS, and AceView
Databases
Complementary DNA (cDNA) for the MAQC A and B
reference RNA samples was shotgun sequenced in 11
separate sequencing runs on the GS FLX platform. A total
of 3.6 million transcriptomer e a d sw e r eg e n e r a t e do f
average length 250 bp, 1.7 million for Sample A and
1.9 million for Sample B. Two different protocols were
compared in this study for the preparation of cDNA from
the RNA samples: 1) ODT: an OligoDT reverse transcrip-
tion (RT) protocol to generate double stranded cDNA
which was then converted into a single-stranded library
for sequencing and 2) TSEQ: a random primer RT
process directly to single-stranded cDNA library for
Transcriptome Sequencing. [See Additional file 1 for
Supplementary Methods for full details.]
The reads were mapped to the human genome and to the
RefSeqdatabaseofwell-annotatedRNAsequencesusingthe
ExpressSeq pipeline implemented on a Windows Desktop.
To evaluate the coverage of the expressed sequences, only
the best BLAST alignment with the smallest e ≤ 10
-20 value
was counted as a hit. Table 1 provides a summary of these
mapping results for both the ODT and TSEQ protocols.
Overall more than 90% of the reads mapped to genomic
DNA, while only 58–73% of the reads mapped to RefSeq
gene sequences, indicating that there are still many more
expressed sequences to be included in RefSeq. Only a small
number of reads (3–10%) failed to map to the human
genomewithe≤10
-20.Althoughsomeoftheseunmappable
reads may be poor quality reads or sequencing artifacts,
many may still represent novel spliced exons or edited
transcripts worthy of further study.
Of the 2.3 million reads that mapped to the RefSeq
sequences, approximately 80% aligned to the well
annotated mRNA sequences denoted with an NM
identifier while the remaining RefSeq reads hit the
predicted XM mRNA sequences or the well annotated
or predicted regulatory sequences designated by NR and
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mately 60% of the pooled cell line NM reads and 45% of
the brain NM reads mapped to the protein coding
regions identified in the Consensus Coding Sequences
(CCDS) database which suggests that transcripts in the
brain tend to have longer 3' UTRs.
Finally, since the AceView databases of expressed
transcripts provides the most comprehensive listing of
spliced and unspliced human mRNAs compiled from all
public cDNA sequences, we applied the ExpressSeq
pipeline to count all reads that hit sequences in the
AceView database of 278,260 "good" genes and their
splice variants that are supported by at least 6 over-
lapping GenBank sequences or encode a putative
protein. Table 1 shows that an additional 10 – 27% of
the total reads hit at least one of these AceView genes and
splice variants that are not yet described by the RefSeq.
Depth and breadth of gene coverage
Since the shotgun sequencing procedure is expected to
provide a random sampling of the different cDNA
strands, most of the reads will hit the most abundant
genes. Consequently, more sequencing reads must be
generated to detect the less abundant genes. Fig. 1a and
Fig. 1b show how increasing numbers of genes are
detected as the number of reads is increased using
multiple sequencing runs on the MAQC A and B
samples. In the upper curves we have plotted the
numbers of NM genes in the RefSeq database that are
hit by at least 1 read as a function of the total number of
reads that hit any NM genes. As the numbers of reads
increase, the numbers of different NM genes detected
increases rapidly and then gradually approaches satura-
tion. [See Additional file 2 for the hit counts to the NM
genes for all sequencing runs.]
These detection curves indicate that after 200,000 –
300,000 reads are generated which map well to any NM
gene in the RefSeq database (corresponding to 1 full
sequencing plate on the GS FLX), the detection of new
genes in the A and B samples by at least 1 hit reaches a
level of approximately 60% of all of the 24,654 NM genes
in RefSeq. With increasing numbers of reads the detection
of new genes continues to increase at a decreasing rate.
Combining all of the approximately 1,000,000 mapped
reads from both the ODT and TSEQ sample preparations,
the depth of gene coverage increases to 73% of all NM
genes for both the pooled human cell lines (A sample)
and the human brain (B sample). Even with one million
mapped reads the detection curves in Fig. 1 do not appear
to have reached saturation. It is likely that deeper
transcriptome sequencing would detect even more of
the less abundant genes in these transcriptionally com-
plex reference RNA samples.
Data points for the detection of genes with at least 10 and
100 hits are also displayed in Fig. 1 corresponding to 1×
and 10× coverage of a typical 2500 bp gene. The dotted
curves also indicate how the 1 hit results can be used to
predict the 10 hit coverage curve and the 10 hit results
predict the 100 hit curve, consistent with the assumptions
of random sampling of the cDNA samples [See Additional
file 1 for Supplementary Analysis] Although there are far
fewer genes with 100 hits (~2000 for both the A and B
samples at 1,000,000 mapped reads), there may be
sufficient numbers of reads for the full assembly of gene
sequences and the identification of homozygous and
heterozygous SNPs for these most abundant transcripts [8].
F i g .1 aa n dF i g .1 ba l s os h o wac o m p a r i s o no ft h ed e p t h
of coverage provided by the two different sample
preparation protocols. The ODT method appears to be
slightly more sensitive in detecting rare genes than the
TSEQ method, perhaps due the shorter effective gene
length caused by 3' bias in the cDNA synthesis. These
differences are illustrated in Fig. 2a and Fig. 2b which
show the breadth of the transcript coverage for the two
protocols for the long (greater than 10,000 bp), medium
(between 2,500 and 10,000 bp), and short (less than
2,500 bp) transcripts. As expected the TSEQ method
provides more uniform coverage of the transcripts from
the 5' to 3' end for transcripts of all sizes; however, the
Table 1: ExpressSeq read counts that hit* NCBI databases
TSEQ TSEQ ODT ODT
MAQC A MAQC B MAQC A MAQC B
Total # of Reads 823,575 1,079,508 881,555 846,304
Reads that Hit Human Genomic DNA 89% 96% 97% 96%
Reads that Hit Human RefSeq (38,698 sequences) 60% 58% 73% 67%
Reads that Hit Human NM's (24,654 sequences) 53% 50% 59% 45%
Reads that Hit CCDS (17,751 sequences) 31% 23% 35% 20%
Reads that Hit AceView (278,760 sequences) 77% 85% 83% 84%
Orphan Reads (Hit none of the above) 10% 4% 3% 4%
*An ExpressSeq "hit" is the single best BLAST alignment of the GS FLX reads to sequences in each database with e ≤ 10
-20.
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the longest transcripts where the coverage density
decreases only 50% from the 3' to 5' end.
Reproducibility of expression levels
The number of reads that map to specific transcripts
provides a direct quantitative measure of the gene
expression level in the sample. Unfortunately, uncertain-
ties in the length and uniformity of coverage of
individual genes and the relative efficiencies of the
reverse transcription (RT) reactions used to transform
RNA into cDNA currently prevent this digital readout
from being used as an absolute measure of gene
expression. Nevertheless, it can still be effectively used
to quantify the relative expression of transcripts in
different samples. In particular, for computing gene
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Figure 1
Depth of transcriptome sequencing coverage.T h e
number of RefSeq NM genes detected by transcriptome
sequencing increases with the total number of reads that hit
any NM gene, N, accumulated in multiple sequencing runs.
The coverage curves, C, show how the number of genes
detected approaches saturation for (a) the A sample and (b)
the B sample as the total number of reads that align to any
NM gene (with e ≤ 10
-20) increases using both the ODT (blue
diamonds, solid line) and TSEQ (red squares, dashed line)
methods of sample preparation. The figures also show the
numbers of genes that receive at least 10 and 100 BLAST hits
from the GS FLX reads (for ~1× sequence coverage of a
typical 2500 bp mRNA). The single points at the far right of
the figures show the combined results from both sample
preparation methods. Since the coverage function for
random sampling obeys the approximate scaling relationship,
Cn(N) ~Cn/x(N/x),w h e r en is the minimum number of hits, the
coverage curve for 10 hits can be predicted from the
empirical results for 1 hit, and the coverage curve for 100
hits from the results for 10 hits, as indicted by the dotted
curves. [See Additional file 1 for Supplementary Analysis]
Figure 2
Shotgun transcriptome sequencing covers gene
sequences from the 5' to 3' ends.T h et r a n s c r i p t
coverage for both the (a) random primer TSEQ and (b)
Oligo DT sample preparation protocols are compared for
short (< 2,500 bp), medium (>2,500 bp and < 10,000 bp),
and long (> 10,000 bp) RefSeq genes. The x axis divides the
transcripts into 20 bins from the 5' to 3' end and the vertical
bars plot the number of unique reads that BLAST with e ≤
10
-20 into each bin for the long (blue), medium (red), and
short (yellow) genes. The coverage is determined by
counting the numbers of reads that align to the RefSeq
sequence with 5' end in each bin. The apparent decrease of
coverage at the 3' end for each method is due to reduced
probability that the average 250 bp reads will start in the 3'
extreme > 90% bins, for shorter genes < 2500 bp.
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length of the gene and the RT efficiency should factor out.
The first metric examined in the MAQC project was
reproducibility of gene expression levels [1]. For shotgun
transcriptome sequencing, this metric can be evaluated
by comparing the fraction of reads that hit each
transcript in multiple sequencing runs and measuring
the coefficient of variation (CV) of the read counts.
Fig. 3a shows a typical scatter plot of the hit counts for
each of the 36,698 RefSeq genes measured for the same
sample preparation on two regions of the same sequen-
cing plate. In this example, both sequencing regions had
approximately the same numbers of total reads and the
straight diagonal line shows the expected read counts if
both sequencing regions measured equal expression
levels. The results are similar when the same sample
preparation is run on two different sequencing plates.
However, gene specific differences do arise when
comparing the counts from the two different (ODT and
TSEQ) sample preparation methods which suggests that
different methods of generating cDNA from RNA may
provide the largest source of variability in the absolute
read counts. (Data not shown.)
For the 140,000 – 150,000 reads used to generate Fig. 3a,
the dynamic range spanned only 3 orders of magnitude
up to ~1000 hits for the most abundantly expressed gene.
However, for random sampling this dynamic range is
expected to increase linearly with increasing depth of
coverage, N. In addition, the variability from the ideal is
well described by a simple Poisson sampling model for
the shotgun sequencing process which predicts that the
hit count CV should decrease with increasing hit number,
N,a s1/ N . Consequently, the median CV of the
expression levels is expected to be < 10% for genes with
N > 100 Since the best microarray platforms inthe MAQC
study achieved median CV's < 10%, this Poisson error
modelpredictsthatthelevelofreproducibilityofthegene
expressionmeasurementsfromtranscriptomesequencing
will be comparable to the DNA microarrays for genes that
have been detected by at least 100 reads. This random
sampling error model, requiring no background correc-
tion, is much simpler than most error models for
microarray-based gene expression data. Moreover, both
t h ed y n a m i cr a n g ea n dC Vo ft h et r a n s c r i p t o m eg e n e
expression measurements exhibit systematic improve-
ment with increasing depth of coverage, N.
Accuracy, sensitivity, and specificity
Additional metrics considered by the MAQC studies for
the evaluation of gene expression platform performance
include the three interrelated measures of accuracy,
sensitivity, and specificity [1]. The relative accuracy of
the gene expression levels inferred from transcriptome
read counts can be assessed by comparing the fold
changes of differentially expressed genes between the A
and B samples with the DNA microarray and with
QRTPCR results from the MAQC study. Fig. 3b shows a
comparison of the fold-changes measured using tran-
scriptome sequencing of the A and B samples with the
TaqMan results for 217 RefSeq genes that were detected
at sufficient levels to be called "present" in both the A
and B samples by TaqMan and by all the major
commercial microarray platforms (ABI, Affymetrix,
Agilent, GE, and Illumina) [1,2]. This scatterplot shows
that the ExpressSeq results for gene expression changes
show excellent correlation with the corresponding Taq-
Man results with a Pearson correlation of R
2 = 0.81. By
comparison the Pearson correlations for the microarray
measurements with TaqMan for these same 217 genes
were Affymetrix (0.75), Agilent (0.80), and Illumina
(0.73). [See Additional file 1 for Supplementary Figure]
The success of sequencing based expression profiling is a
result of the high sensitivity of transcriptome reads in
1000 6
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Figure 3
Performance of the GS FLX transcriptome
sequencing evaluated using the MAQC metrics for
reproducibility and accuracy.( a) The reproducibility of
the ExpressSeq gene counts is displayed using a scatterplot of
the numbers of uniquehits for different RefSeq genes counted
in two sequencing regions on the same sequencing plate using
the TSEQ sample preparation method. The total numbers
BLAST hits to RefSeq genes in each region were 153,697 and
139,962. The solid blue line indicates the ideal result of equal
fractions of gene hits for each sequencing region and the two
solid, yellow and red, curves show the median CV's ~1/ N
predicted by the Poisson sampling error model. (b)T h e
relative accuracy of the ExpressSeq gene counts is illustrated
with a scatterplot of the log base 2 fold-changes (FC) in gene
expressionlevelsfortheMAQCAandBsamplesonthey-axis
compared with the TaqMan measurements from the original
MAQC study on the x-axis for 217 RefSeq genes that were
called "present" in both samples by TaqMan and the
microarray platforms. The trendline shows the best fit with
Pearson correlation R
2 = 0.81.
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(page number not for citation purposes)detecting and counting these abundant genes. For each
of the 217 genes called "present" in both the A and B
samples on every microarray platform and individual
TaqMan assays, the 3.6 million reads generated by the
transcriptome sequencing gave at least one hit in both
the A and B samples with a maximum of 1944 hits and a
median of 55 for the A sample and a maximum of 1226
hits and a median of 46 for the B sample. These numbers
translate to median read counts of ~25 reads per gene per
million mapped reads. Since the detection limit for a
"present" call on DNA microarrays is frequently esti-
mated to be ~1 copy per cell [19], the ExpressSeq results
are in good agreement with the estimates presented in
Ref. [13] that a gene present at the level of 1 copy/cell
should yield at least 3 shotgun reads per kbp per million
mapped reads (RPKM) or 6 reads per (2 kbp) gene per
million mapped reads.
High specificity is also necessary for accurate measures of
gene expression changes since signals associated with
more than one gene can mask the true expression level of
a rare transcript. For example multiple reads from repeat
regions such as Long Interspersed Nuclear Elements
(LINEs), Short Interspersed Nuclear Elements (SINEs),
and ALUs in the untranslated regions of the transcrip-
tome can distort the true expression level. The Express-
Seq pipeline avoids this problem with a stringent
requirement that each read to be counted only once for
the best BLAST hit to each RefSeq. As an illustration, for a
highly expressed, brain specific genes, such as the Myelin
Basic Protein (MBP), there were a total of 5653 unique
reads that hit the 5 annotated splice variants in RefSeq
for the MAQC brain sample B while only 52 reads hit the
MAQC pooled human cell lines sample A. This dynamic
range of 109-fold difference compares well with the
DNA microarray measurements for the same gene in the
A and B samples, Affymetrix (85-fold), Agilent (210-
fold), and Illumina (99-fold).
Discovery of New Splice Variants
The AceView database of transcribed sequences was
generated by co-aligning all publically available cDNA
sequences generated in the past 15 years of Sanger
sequencing to the human genome [18] The same
alignment software was used here to successfully map
88% of the long GS FLX reads for the MAQC A and B
samples to the NCBI Build 36.3 of the human reference
genome with the requirement that over 90% (on average
> 245 bp) of the entire sequence align perfectly.
Table 2 shows that this alignment of the MAQC reads
proved very useful for the discovery of alternative spliced
exons in the A and B samples. Using the AceView
software we have identified 137,899 unique exon
junctions. [See Additional file 3.] These were defined
by the stringent requirement that two exons are
separated by a standard intron with GT-AG (99.35%),
GC-AG (0.6%), or AT-AC (0.05%) on either end with at
least 8 consecutive bases that perfectly match the exon
sequences on each side of the junction.
Using these criteria, the 3.6 million MAQC reads
recovered over 60% of the 199,469 exon junctions
currently supported by cDNA sequences in the March 24,
2008 release of RefSeq. In addition these GS FLX reads
identified 22,193 exon junctions not yet in RefSeq. [See
Additional file 4.] These new exon junctions were
supported by slightly more reads from the TSEQ random
primer sample preparation method (55%) and from the
pooled cell line sample A (57%). Although 62% of these
novel exons junctions have already been described in the
comprehensive AceView database culled from all pub-
licly available cDNA sequences (GenBank, RefSeq,
dbEST, and TRACE), 8,432 appear to be novel to both
RefSeq and AceView.
From the 22,193 new exon junctions we also identified
912 cassette exons defined by the requirements that the
GS FLX reads support both bordering GT-AG intron-exon
boundaries inside of an intron already defined by RefSeq.
Although 662 were already represented in the AceView
database, the GS FLX reads provided support for 250
n o v e lc a s s e t t ee x o n s .[ S e eA d d i t i o n a lf i l e4 . ]I na d d i t i o n ,
the GS FLX reads identified 504 new exon junctions that
skip exons in RefSeq genes and 192 of these junctions
events were new to the AceView database as well. [See
Additional file 4.] In this analysis, the new cassette exon
andskippingexoneventswereonlycountedasalternative
splicing events if other GS FLX reads also supported the
conventional RefSeq junctions for these genes.
Not surprisingly, the conventional RefSeq exon junctions
were biased to the more commonly expressed junctions
with an overall average support of 39.1 GS FLX reads,
Table 2: Exon junctions* identified by alignment of the GS FLX
reads from the MAQC A and B Samples to the Human Genome
compared with RefSeq and AceView
RefSeq MAQC AceView
Total Number of Exon
Junctions
190,325 137,899 360,517
Number of Exon
Junctions not in RefSeq
0 22,193 170,557
Number of Novel Exon
Junctions not in RefSeq
or AceView
0 8,432 0
*Exon junctions were identified by the requirements that the reads align
to the genome separated by standard GT-AG, GC-AG, or AT-AC
introns.
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(page number not for citation purposes)while the additional junctions also found in AceView
were supported by an average of 3.5 FLX reads and the
novel candidate junctions by an average of 1.3 reads.
Since the MAQC A sample consists of pooled RNA from
10 different cell lines, it might be expected that some of
the novel exon junctions may arise from abnormal
chromosomal arrangements in these immortalized cells.
However, the B sample from normal human brain tissue
contributed comparable numbers of novel exon junc-
tions: 51% in B, 52% in A and 3% in both.
Finally, we note that the ExpressSeq results can be used
to directly measure the differential expression of both
the novel and well documented transcript variants,
providing a complementary platform to the new exon
microarrays. For example, Fig. 4 compares the transcrip-
tome sequencing results with the Affymetrix exon array
measurements for two transcript variants of the ELAVL1
found in the original MAQC studies to be differentially
expressed in the MAQC A and B samples [2].
Discussion
Transcriptome sequencing using the massively parallel,
next-generation sequencing technologies provides a
high-throughput method for rapidly generating millions
of reads for expressed sequences from different RNA
samples [3,4,6-13,15,20]. These reads can be used to
verify predicted genes and discover new transcription
products and the expression levels can be quantified by
direct counting of the numbers of reads mapping to
different genes and transcript variants. In addition Single
Nucleotide Polymorphisms (SNPs) in both the coding
and noncoding regions of expressed genes can be
identified by comparing the sequences of multiple
matching reads with reference sequences [8]. In the
past year these new technologies have already provided
radically new insights into the transcriptional complexity
of a number of different organisms from bacteria [9], to
yeast [10,11], plants [6,7], mouse [12,13], and man
[5,8,15,16] As the new sequencing technologies strive
toward the capability of sequencing the entire human
genome for $1000, these approaches will become
routine tools for every facet of gene expression analysis.
In this paper we have focused on the quantification of
gene expression levels and have compared the results
with DNA microarrays and Quantitative RTPCR using
the Microarray Quality Control (MAQC) reference RNA
samples [1,2]. We have generated 3.6 million reads of
average length 250 bp on Roche's 454 GS FLX for the
MAQC A and B reference RNA samples. Using the
ExpressSeq pipeline these reads can be easily mapped to
the human RefSeq genes on a Windows desktop
computer and gene expression levels conservatively
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Figure 4
Transcriptome sequencing detects differentially
expressed transcript variants. Because of the diverse
nature of the MAQC A and B samples it is expected that
there may be many genes with differentially expressed
transcript variants. For example the original MAQC study
found that the ELAVL1 gene was more highly expressed in
Sample B than A on microarrays with probes designed to the
3' end of the gene, but more highly expressed in sample A on
microarrays and the TaqMan, StaRT-PCR, and Quantigene
with probes in the 5' end. Using the transcriptome sequences
from both the ODT and TSEQ preparations, the differential
expression of the two transcript variants in the A and B
samples resulting from alternative polyadenylation sites is
immediately clear. (a) The BLAST start and end positions of
each read are plotted on the x and y for every read that hit
t h eE L A V L 1g e n ei nS a m p l e sA( r e dp o i n t s )a n dB( b l u e
points). Plotted this way, the forward reads correspond to
t h ep o i n t sa b o v et h eg r a y4 5d e g r e el i n ea n dt h er e v e r s e
reads below. The reads for the brain Sample B cover the
entire 6075 bp length of the RefSeq gene from the 5' to 3'
end while most the reads for the pooled cell line Sample A
hit a much shorter transcript with a truncated 3' UTR. This
conclusion is also confirmed by the Affymetrix Exon 1.0
array. (b) The hybridization results for the core exon
probesets for the ELAVL1 gene are plotted for Samples A
(red points) and B (blue points) showing the differential
expression of the short and long transcript variants. The
black and grey bars at the top of (b) show the coordinates of
the 6 exons of ELAVL1. The red diamonds indicate an
alternative polyadenylation site in the middle of the 6
th exon
identified by AceView.
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(page number not for citation purposes)determined by simply counting the numbers of unique
hits with e-values ≤ 10
-20.
Using the MACQ quality metrics for evaluating the
reproducibility, sensitivity, specificity, and accuracy of
the gene expression analysis, we have demonstrated that
these ExpressSeq results already compare favourably
with the results for DNA microarrays and QRTPCR in the
MAQC studies. Moreover, a simple Poisson error model
for the random shotgun sequencing process describes
how these metrics systematically improve with increased
numbers of reads.
The presence of repeated sequences arising from homo-
logous gene families and from LINE, SINE, and ALU
elements in untranslated regions of the transcriptome
pose a significant challenge to the accurate quantifica-
tion of gene expression by read counts. This is a problem
that is well appreciated by the DNA microarray and
QRTPCR communities that have been very careful to try
to avoid these problems by carefully designing gene
probes and primers. Here we have tried to minimize the
problem by counting each read only once. However,
quantitative errors from the miss-assignment of this read
are inevitable. Better strategies for dealing with reads
with multiple alignments are required. For example,
reads with multiple equivalent alignments to the
genome could be eliminated altogether or reads counted
only when they map to gene coding regions or to known
exons [13].
We have also used the AceView alignment software [18]
to co-align these 3.6 million reads for A and B samples to
the human genome to identify over 20,000 new exon
junctions in the human transcriptome. Although these
candidate exon junctions may be less common than the
well-annotated RefSeq junctions, they may still play an
important role in determining the diversity of biological
phenotypes. These results indicate that there is still a
significant amount of biology to be uncovered using
transcriptome sequencing.
At present genomics researchers can choose among
several next-generation sequencing platforms for tran-
scriptome sequencing that generate either long, 250 bp–
400 bp, (Roche GS FLX) or short, ~30 bp, (Illumina
Genome Analyzer and ABI SOLiD) reads. The larger
numbers of reads generated by the short read platforms
provide greater sequencing depth and should provide
better reproducibility, sensitivity, specificity, and accu-
racy for the measurement of differential gene expression.
However, the longer reads are easier to map and to
assemble. Consequently, the long reads should be better
for the discovery and assembly of novel genes and splice
variants.
For example, three papers have recently appeared with
deep sequencing results for transcriptomes of different
human cell lines [21,22] and tissues [22,23] using the
Illumina Genome Analyzer. Although these studies
generated between 16 million [21] and 435 million
[22] reads for expressed transcripts, they succeeded in
only identifying between 4096 [21] and 11,099 [23] new
exon junctions not contained in the human Ensembl and
RefSeq databases by aligning the short, 32 bp, reads to
databases of predicted splice junctions. In particular, the
largest study [22] with more than 400 million reads
discovered only 114 new "isolated" cassette exons in all
of the 15 human tissues and cell lines examined, as
compared with the 912 new cassette exons found here by
aligning 3.6 million long reads for the MAQC samples
directly to the human genome.
A remaining challenge is the proper assembly of the
transcribed exons into the full-length alternative tran-
scripts [24]. This will require preservation of the identity
of the transcribed strand to distinguish reads from
overlapping transcripts (which can be accomplished
using a modification of the TSEQ protocol) and longer
read lengths and/or paired end reads for the transcrip-
tomes will be necessary to link all of the pieces together.
Fortunately, the new GS FLX Titanium upgrade now
provides average 400 bp reads and all of the new
sequencing platforms have protocols for paired end
reads to bridge across the full length transcripts. As read
lengths and throughput continue to increase and new
sequencing platforms [25-27] and software tools [28] for
mapping the reads emerge, the combination of the long
and short read technologies may be most effective for
exploring the complexity of the transcriptome, where
the long reads are used for gene discovery and assembly
and the short reads for confirmation and quantification
[22].
Conclusion
Gene expression analysis by transcriptome sequencing
using the next-generation sequencing technologies
shows great promise. Using the metrics introduced for
evaluating the performance of gene expression platforms
in the MAQC studies, our ExpressSeq results for gene
expression levels of the MAQC reference RNA samples
showed excellent specificity, sensitivity, and reproduci-
bility that improve systematically with increasing
sequencing depth, and quantitative accuracy that com-
pare favourably with DNA microarrays and Quantitative
RT-PCR. In addition, a careful mapping of the long GS
FLX reads to the genome using the AceView alignment
programs shed new light on the complexity of the
human transcriptome including the discovery of thou-
sands of new splice variants.
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RNA Samples
Sample A is Universal Human Reference RNA (Strata-
gene catalog # 740000) from pooled human cell lines
and Sample B is FirstChoice Human Brain Reference
Total RNA (Ambion catalog # AM6051) from pooled
whole brain preparations. The two samples are identical
to the total RNA samples used throughout the MAQC
studies.
Sample Preparation
Two different general methods for preparing cDNA for
sequencing were compared in this study. [See Additional
file 1 for Supplementary Methods for full details]
1) An Oligo DT (ODT) protocol, similar to the process
used to prepare samples for DNA microarray studies, was
utilized to prepare double stranded cDNA for the
standard Roche GS DNA Library preparation and
sequencing process. For some sequencing runs modified
oligo dT primers ending with two different additional
nucleotides were introduced to help eliminate reads with
long poly A strings.
2) A Transcriptome Sequencing (TSEQ) protocol using
random primers was applied to heat-fragmented mRNA
strands to generate a single stranded cDNA library for
sequencing using the standard Roche GS Amplicon
sequencing process. It was hoped that the use of random
primers would remove a potential 3' bias in the ODT
preparation.
In all cases, a thorough depletion of rRNA, which can
constitute as much as 98% of the total RNA, was
required to minimize the numbers of sequencing reads
from rRNA contamination, even for the ODT protocol.
Several different methods for rRNA depletion were tested
for the ODT protocol in different sequencing runs
ranging from a simple ribo-reduction step to multiple
mRNA enrichment steps while the TSEQ protocol
consistently utilized a rigorous 2 step mRNA enrichment
using magnetic beads. When multiple rRNA reduction
steps were used, the rRNA reads were reduced to less
than 10% of the total.
Sequencing and Signal Processing
The samples were sequenced using the standard GS FLX
protocol. The single stranded cDNA libraries (with
ligated adapters) are annealed to DNA sequencing
beads and then clonally amplified using emulsion PCR
(emPCR). Hundreds of thousands of the DNA library
beads are deposited onto 44 micrometer diameter wells
on a PicoTiterPlate and sequenced by synthesis, where
successive incorporation of nucleotides are imaged using
chemoluminescence with a CCD camera on the GS FLX
instrument. The image analysis, signal processing and
data filtering are performed using the standard 454
Software with the "decreased stringency" and "lowest
stringency" settings: vfLastFlowToTest = "168" and
vfBadFLowThreshold = "6". The lower stringency settings
on the read quality filters result in 20–50% more useful
reads from the sequencing runs for mapping to the
reference sequence databases. Finally, all of the reads
that pass the quality filters are deposited into the output
files in flowgram (.sff) and FASTA (.fna) formats for
further analysis and have been archived at the NCBI
Short Read Archive Accession [NCBI:SRA003647].
ExpressSeq pipeline for read mapping
Eleven full GS FLX sequencing runs were completed for
this study for cDNA prepared from the MAQC A and B
samples using different protocols described above. Each
sequencing run generated up to 500,000 reads on the
large LR75 sequencing plates divided into two regions. In
most cases the A and B samples were run simultaneously
in two regions on the same plate. In a few cases the same
sample was run in both regions to compare the inter-
and intra-run reproducibility of the sequencing results.
[See Additional file 1 for Supplementary Table for a
guide to the sequencing runs]
The ExpressSeq pipeline maps each of the long reads to
the Human Genome or the RefSeq (Build 36.2), CCDS,
and AceView databases of expressed sequences from July
2007 using MegaBlast on Windows desktop computer or
TeraBLAST implemented on a TimeLogic DeCypher. The
vast majority of the long reads could be mapped
unambiguously to the reference databases with default
BLAST parameters and e-values ≤ 10
-20 or better,
corresponding to at least 50 perfect match bases. Several
hundred thousand reads could be easily mapped to the
38,698 RefSeq or 17,751 CCDS sequences in a few hours
of CPU time on the Windows Desktop while the mapping
of all of the 3.6 million reads in this study could be
mapped to either the much larger AceView database in an
overnight run or to the entire human genome in 6 days
using the TimeLogic DeCypher accelerator board.
Expression levels could then be inferred by simply
counting the number of reads in each sample that hit
each reference sequence. A number of reads were found
to hit regions associated with repeat elements such as
LINEs, SINEs, and ALUs that may occur even in
expressed sequences, especially 3' UTRs. Since these
ambiguous hits will skew the inferred gene expression
levels, each read was only counted once for the single
best hit with smallest e-value. No effort was made here
to resolve "ties", only the first "best" hit in the BLAST
output files was counted.
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to multiple locations in the genome with e ≤ 10
-20 in all
samples and sample preparations, multiple equivalent
hits to RefSeq sequences can frequently arise when two
or more splice variants of the same gene are present with
different accession numbers. Here, the fraction of
ambiguous reads increases to 20 – 26%. In these cases
only the reads associated with specific exons or exon
junctions can be unambiguously assigned to specific
splice variants. Consequently, for comparison with the
DNA microarray and QRTPCR data, the ExpressSeq
pipeline simply sums the hits for all splice variants of
t h es a m eg e n et oi n f e rt h ee x p r e s s i o nl e v e lo ft h e" g e n e " .
The BLAST output files used for the hit counts also
provide the start and stop sites of the read alignments to
Reference so that the locations of the hits can be
determined to assess the 5' to 3' coverage of the GS
FLX reads. An Excel spread sheet with the ExpressSeq
read counts for the RefSeq NM genes for each
sequencing run for Samples A and B is provided [see
Additional file 2]
Read alignment to the genome using AceView
A different approach to read mapping is provided by the
AceView software. The AceView database and website
provides a curated, comprehensive, and non-redundant
sequence representation of all public mRNA sequences
(from the GenBank, RefSeq dbEST and Trace databases).
This was accomplished by co-aligning all publicly
available mRNAs and ESTs onto the genome sequence,
using an original cDNA-to-genome coalignment pro-
gram, initially called Acembly.
Because of the high quality of the long GS FLX reads,
with sequencing errors (primarily due to homopolymer
insertion and deletions) of less that 1%, these expressed
sequences reads could be aligned with exactly the same
software settings as used for the public collection of
ESTs and cDNAs from Sanger sequencing over the past
15 years.
The best alignment for each read was determined with
the stringent requirement that over 90% (on average >
245 bp) of the entire sequence align perfectly to the
human genome. When the alignment covered disjoint
segments on the same chromosome separated by
traditional introns with boundaries defined by GT-AG,
GC-AG, or AT-AC (0.05%) with at least 8 consecutive,
perfect match bases on each side of the intron, the read
was counted as spanning an exon boundary. With these
strict requirements, thousands of new exon splice
sites were identified including 100's of new cassette
exons that had not been previously experimentally
observed.
The genomic locations of the 137,899 unique exon
junctions and the identities of the supporting reads from
the A and B samples are provided in tab delimited
format [see Additional file 3]. An Excel Spreadsheet
containing the locations and supporting reads for the
candidates for new cassette exons and skipped exons is
provided [see Additional file 4]. This file also contains a
list of diseases associated with the genes where these new
splicing events are found.
Affymetrix exon arrays
The MAQC A and B RNA reference samples were
analyzed using the Affymetrix Human Exon 1.0 Gene-
Chips using standard Affymetrix protocols and the data
analyzed using the RMA algorithm in the Affymetrix
Expression Console software to identify differential
expression at the exon level for comparison with the
ExpressSeq results [29].
Accession numbers
A l lt r a n s c r i p t o m es e q u e n c i n gd a t af r o mt h i ss t u d ya r e
available through the NCBI Short Read Archive Acces-
sion number [NCBI:SRA003647] including the raw
standard flowgram files (SFF) and the read fasta (FNA)
files. The Affymetrix Exon array data is available at GEO
Accession number [NCBI:GSE13072].
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Supplementary Materials. Contains detailed Supplementary Methods
for the preparation of the samples for Transcriptome Sequencing, the
Supplementary Analysis for determining the scaling properties of the
depth of coverage curves, the Supplementary Figure comparing the
relative accuracy of the ExpressSeq results with different microarray
platforms, and the Supplementary Table containing the guide to the
different sequencing runs and data files.
Click here for file
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ExpressSeq Read Counts for the A and B Samples. An Excel Workbook
provides the NM "hit" counts for each of the 22 sequencing regions on
the 11 full GS FLX sequencing plates described in Supplementary Table
1 in Additional file 1. The Excel file contains 4 Worksheets providing the
hit counts for the sequencing runs for the A and B samples processed
using either the TSEQ or ODT protocols. The first 2 columns of each
Worksheet contain the RefSeq NM number and description. The third
column provides the RefSeq transcript length and the subsequent
columns give the numbers of reads that hit each transcript with
evalues < 1.0e
-20 for each sequencing region.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-264-S2.xls]
Additional file 3
All Standard Exon Junctions. This compressed tab delimited text file
contains the genomic locations (by chromosome number and position) of
each of the 137,899 standard exon junctions identified by the stringent
AceView alignment of the 3.6 million reads for the MAQC A and B
samples generated in this study. In addition, the supporting reads are listed
for each junction using the unique alphanumeric names for each sequencing
run. [See the Supplementary Table of Additional file 1 for a guide.]
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-264-S3.gz]
Additional file 4
New Cassette Exons and Skipped Exons. The first Worksheet of this MS
Excel file contains the genomic locations (by chromosome number and
position) and the identities of the supporting reads for each end of the 912
new cassette exons found inside of a RefSeq intron identified by the stringent
AceView alignment of the 3.6 million reads for the MAQC A and B samples
generated in this study. The second Worksheet contains the locations of the
249 novel candidate cassette exons that had not been previously identifiedby
either RefSeq or AceView. The third and fourth Worksheets provide the
genomic locations and supporting reads of the 504 new skipped exons absent
in RefSeq and the 192 novel skipped exons missing from both RefSeq and
AceView. The sequences for the supportingreads for each exon boundary can
be found in the Short Read Archives Accession Number [NCBI:
SRA003647] with the assistance of the Supplementary Table in the
Additional file 1.Thelast twoWorksheetsprovidea listofdiseasesassociated
with the gene loci where these new cassette and skipped exons are found.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-264-S4.xls]
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